ESMO 2026: CheckMate 8HW – Final Overall Survival Results
Final overall survival results from the phase III CheckMate 8HW trial were presented in a late-breaking abstract by Dr. Sara Lonardi, MD, Chief of Medical Oncology at the Veneto Institute of Oncology, Padova, Italy, at ESMO 2026. Nivolumab plus ipilimumab demonstrated a significant overall survival benefit compared with chemotherapy and nivolumab alone in patients with MSI-H/dMMR metastatic colorectal cancer. In the first-line setting, the combination also showed an improvement in five-year overall survival compared with nivolumab alone.







